Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | LAP3 | P28838 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412128 | 0.91 | CA2 (0.72) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL80651 | 0.89 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL4658540 | 0.89 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL10866230 | 0.89 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL2481659 | 0.89 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL3235440 | 0.89 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL2089080 | 0.89 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL16098865 | 0.89 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL20746502 | 0.89 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 | |
| SCHEMBL10866159 | 0.89 | CA2 (0.68) | CA2CA1GRIK1GRIK2SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, MRPS35 | CA2 4668/4885CA1 4849/4885GRIK1 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.